Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

Trial Details

NCT ID

NCT06839560

Phase

PHASE2

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy
• Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Males or females who are at least 18 years of age on the day of signing the informed consent form.
• Patients with metastatic HER2-negative breast cancer brain metastasis, with clear clinical documentation; specific criteria refer to the guidelines…
• Patients who have received no more than one line of chemotherapy during the metastatic stage of breast cancer.
• Patients with brain metastasis should not require immediate local therapy during the trial and meet at least one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.